Phase 2 Breast Cancer Trial, Recruiting (NCT07610720)

Phase 2 Breast Cancer Trial, Recruiting NCT07610720 Sponsor: Sun Yat-sen University Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07610720 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women between 18 and 75 years old whose breast cancer has been confirmed by a laboratory test to have spread to other parts of the body or to be locally advanced and unable to be removed by surgery
People whose cancer tests positive for both hormone receptors (HR) and a protein called HER2
People whose cancer has not gotten worse (meaning it has either disappeared, shrunk, or stayed the same) after 4 to 8 rounds of their first treatment for advanced breast cancer
People who are generally well enough to carry out everyday activities, with little to no limitation (this is measured by a medical scoring system called ECOG, with a score of 0 or 1)

Who may not be able to join:

People who have active brain metastases (cancer that has spread to the brain) causing symptoms, or widespread spread of cancer to the lining around the brain and spinal cord
People who have previously had a severe allergic reaction (Grade 3 or 4) to the medications being used in this trial
People who are currently receiving any other cancer treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 02087341812

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07610720

Sponsor: Sun Yat-sen University

Phase: Phase 2

Status: Recruiting

Condition: Breast Cancer

Trial contact: 02087341812

More information: https://clinicaltrials.gov/study/NCT07610720

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women between 18 and 75 years old whose breast cancer has been confirmed by a laboratory test to have spread to other parts of the body or to be locally advanced and unable to be removed by surgery
People whose cancer tests positive for both hormone receptors (HR) and a protein called HER2
People whose cancer has not gotten worse (meaning it has either disappeared, shrunk, or stayed the same) after 4 to 8 rounds of their first treatment for advanced breast cancer
People who are generally well enough to carry out everyday activities, with little to no limitation (this is measured by a medical scoring system called ECOG, with a score of 0 or 1)

Who may not be able to join:

People who have active brain metastases (cancer that has spread to the brain) causing symptoms, or widespread spread of cancer to the lining around the brain and spinal cord
People who have previously had a severe allergic reaction (Grade 3 or 4) to the medications being used in this trial
People who are currently receiving any other cancer treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Sun Yat-sen University

Registry

ClinicalTrials.gov

Start date

1 June 2026

Est. completion

1 November 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov